160 related articles for article (PubMed ID: 17322542)
1. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Scott L; Soepenberg O; Verweij J; de Jonge MJ; Th Planting AS; McGovern D; Principe P; Obach R; Twelves C
Ann Oncol; 2007 Mar; 18(3):569-75. PubMed ID: 17322542
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
5. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.
Graham JS; Falk S; Samuel LM; Cendros JM; Evans TR
Cancer Chemother Pharmacol; 2009 Apr; 63(5):945-52. PubMed ID: 18654747
[TBL] [Abstract][Full Text] [Related]
6. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Schoemaker NE; Kuppens IE; Huinink WW; Lefebvre P; Beijnen JH; Assadourian S; Sanderink GJ; Schellens JH
Cancer Chemother Pharmacol; 2005 Mar; 55(3):263-70. PubMed ID: 15592838
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
14. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Dumez H; Awada A; Piccart M; Assadourian S; Semiond D; Guetens G; de Boeck G; Maes RA; de Bruijn EA; van Oosterom A
Ann Oncol; 2006 Jul; 17(7):1158-65. PubMed ID: 16600980
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Sharma S; Kemeny N; Schwartz GK; Kelsen D; O'Reilly E; Ilson D; Coyle J; De Jager RL; Ducharme MP; Kleban S; Hollywood E; Saltz LB
Clin Cancer Res; 2001 Dec; 7(12):3963-70. PubMed ID: 11751488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]